DEVELOPMENTAL CANCER THERAPEUTICS

霍林斯癌症中心（HCC）发展癌症治疗（DCT）项目的科学目标是发现和描述独特的药物和途径，这些药物和途径将影响更有效癌症治疗的发展，并通过原理验证、早期临床和相关科学研究将这些发现转化为临床应用。DCT项目由Kenneth D. Tew博士和Carolyn D. Britten医学博士共同领导。DCT项目围绕三个科学研究主题组织：-细胞信号通路的阐明。氧化还原和细胞应激反应的调节。-小分子化疗药物的发展。DCT项目的46名成员，代表医学院和药学院的12个部门，有87项有效的赠款/合同，总计1170万美元的癌症研究资金（7.7美元来自同行评审资金，370万美元来自NCI）。2012年，DCT项目实施了65个早期阶段（试点）。I期、I /ll期和II期)介入治疗临床试验，其中25项由研究者发起；224名患者被纳入所有DCT项目的介入治疗研究。在过去的五年里，DCT项目成员发表了305篇关于癌症的出版物，其中17%代表项目间合作，35%代表项目内合作，48%来自多机构合作。

The scientific goal of the Hollings Cancer Center (HCC) Developmental Cancer Therapeutics (DCT) Program is to discover and characterize unique agents and pathways that will impact the development of more effective cancer therapies and to translate these discoveries into clinical applications by using proof-of principle, early phase clinical and correlative science studies. The DCT Program is co-led by Kenneth D. Tew, PhD and Carolyn D. Britten, MD. The DCT Program is organized around three themes of scientific investigation: � Elucidation of Cellular Signaling Pathways. � Modulation of Redox and Cellular Stress Response. � Development of Small Molecule Chemotherapeutic Agents. The 46 members of the DCT Program, representing 12 departments within the College of Medicine and the College of Pharmacy, have 87 active grants/contracts totaling $11.7M in cancer research funding ($7.7 in peer-reviewed funding and $3.7M from the NCI). In 2012 the DCT Program implemented 65 early phase (pilot. Phase I, Phase l/ll, and Phase II) interventional treatment clinical trials, of which 25 were invesfigator initiated; 224 patients were enrolled onto all DCT Program interventional treatment studies. In the past five years, DCT Program members produced 305 cancer-focused publications with 17% of these representing inter-programmatic and 35% intra-programmatic collaborations and 48% from mulfi-insfitutional collaborations.